Price T Rowe Associates Inc Neogenomics Inc Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Neogenomics Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 432,540 shares of NEO stock, worth $7.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
432,540
Previous 588,594
26.51%
Holding current value
$7.1 Million
Previous $8.16 Million
21.84%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding NEO
# of Institutions
294Shares Held
124MCall Options Held
698KPut Options Held
120K-
Black Rock Inc. New York, NY19.7MShares$323 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA14MShares$230 Million0.0% of portfolio
-
Brown Advisory Inc6.89MShares$113 Million0.13% of portfolio
-
Janus Henderson Group PLC London, X06.6MShares$108 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.54MShares$107 Million0.06% of portfolio
About NEOGENOMICS INC
- Ticker NEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 125,796,000
- Market Cap $2.06B
- Description
- NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytoge...